Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 291–294 | Cite as

Information on risk of constipation for Danish users of opioids, and their laxative use

  • Anton PottegårdEmail author
  • Thomas Bøllingtoft Knudsen
  • Kim van Heesch
  • Hassan Salmasi
  • Simon Schytte-Hansen
  • Jens Søndergaard
Short Research Report

Abstract

Background While it is well known that use of opioids often cause constipation, little is known about the information given to patients regarding this potential side-effect and their use of laxatives to prevent it. Objective To assess the degree of information provided by the prescriber to users of opioids by the time of the first prescription regarding the risk of constipation. Method Interviews with patients filling an opioid at a community pharmacy were performed by the dispensing pharmacist or pharmaconomist at the pharmacy. Information collected concerned the patient, the opioid, information received regarding constipation, current constipation and current laxative treatment. Results A total of 286 interviews were completed. Overall, 28.3 % remembered having received information about the risk of constipation by the time of the first prescription. Excluding 49 first-time opioid users, we found 91 laxative users and 146 non-laxative users, of whom 73.6 and 4.8 %, respectively, currently experienced constipation. Conclusion Only a small proportion of patients with a prescription for opioids remembered having had information on potential constipation caused by opioids and having received any recommendation on how to use laxatives to prevent constipation. Interventions should focus on whether constipation is present and on rational use of laxatives.

Keywords

Constipation Denmark Laxative Opioids Patient information Prescribing 

Notes

Acknowledgments

The authors would like to thank the staff at Copenhagen Sønderbro Pharmacy for their help in collecting the data for the study.

Funding

No external funding was obtained for the study.

Conflicts of interest

The authors report no conflict of interest.

References

  1. 1.
    International Narcotics Control Board. Annual Report 2012. New York: United Nations; 2013.Google Scholar
  2. 2.
    National Institute for Health Data and Disease Control. 2013. www.medstat.dk/en. 4 Apr 2013.
  3. 3.
    Goodheart CR, Leavitt SB. Managing opioid-induced constipation in ambulatory-care patients. Pain Treat Top. 2006; 1–9.Google Scholar
  4. 4.
    Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Sympt Manag. 2010;40:696–703.CrossRefGoogle Scholar
  5. 5.
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347–54.PubMedGoogle Scholar
  6. 6.
    Pedersen KM, Andersen JS, Sondergaard J. General practice and primary health care in Denmark. J Am Board Fam Med. 2012;25(Suppl 1):S34–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Wein S. Opioid-induced constipation. J Pain Palliat Care Pharmacother. 2012;26:382–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Wilson M, Robinson EJ, Blenkinnsopp A, Panton R. Customers’ recall of information given in community pharmacies. Int J Pharm Pract. 1992;1:152–9.CrossRefGoogle Scholar
  9. 9.
    Kinnersley P, Edwards A, Hood K, Cadbury N, Ryan R, Prout H, et al. Interventions before consultations for helping patients address their information needs. Cochrane Database Syst Rev. 2007;CD004565.Google Scholar
  10. 10.
    Pottegard A, Hallas J, Sondergaard J. Pharmaceutical interventions on prescription problems in a Danish pharmacy setting. Int J Clin Pharm. 2011;33:1019–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Schommer JC, Pedersen CA, Worley MM, Brown LM, Hadsall RS, Ranelli PL, et al. Provision of risk management and risk assessment information: the role of the pharmacist. Res Social Adm Pharm. 2006;2:458–78.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Anton Pottegård
    • 1
    • 2
    Email author
  • Thomas Bøllingtoft Knudsen
    • 3
  • Kim van Heesch
    • 2
  • Hassan Salmasi
    • 2
  • Simon Schytte-Hansen
    • 4
  • Jens Søndergaard
    • 3
  1. 1.Clinical Pharmacology, Institute of Public HealthUniversity of Southern DenmarkOdense CDenmark
  2. 2.Copenhagen Sønderbro PharmacyCopenhagen SDenmark
  3. 3.Research Unit of General Practice, Institute of Public HealthUniversity of Southern DenmarkOdense CDenmark
  4. 4.Unit for Patient SafetyThe Capital Region of DenmarkHvidovreDenmark

Personalised recommendations